1. Home
  2. NVNI vs LNAI Comparison

NVNI vs LNAI Comparison

Compare NVNI & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$1.33

Market Cap

13.8M

Sector

N/A

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.34

Market Cap

11.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
LNAI
Founded
2019
N/A
Country
Brazil
United States
Employees
618
29
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
11.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NVNI
LNAI
Price
$1.33
$0.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
389.8K
7.5M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.15
52 Week High
$4.94
$1.66

Technical Indicators

Market Signals
Indicator
NVNI
LNAI
Relative Strength Index (RSI) 50.67 46.92
Support Level $1.10 $0.27
Resistance Level $1.42 $0.54
Average True Range (ATR) 0.11 0.04
MACD 0.02 0.00
Stochastic Oscillator 51.71 39.39

Price Performance

Historical Comparison
NVNI
LNAI

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: